Barrow Hanley Mewhinney & Strauss LLC Sells 2,592,747 Shares of Elanco Animal Health Incorporated $ELAN

Barrow Hanley Mewhinney & Strauss LLC reduced its stake in shares of Elanco Animal Health Incorporated (NYSE:ELAN) by 34.0% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 5,036,147 shares of the company’s stock after selling 2,592,747 shares during the quarter. Barrow Hanley Mewhinney & Strauss LLC owned about 1.01% of Elanco Animal Health worth $101,428,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. SJS Investment Consulting Inc. grew its position in shares of Elanco Animal Health by 2,563.5% during the 3rd quarter. SJS Investment Consulting Inc. now owns 1,385 shares of the company’s stock worth $28,000 after buying an additional 1,333 shares during the period. Huntington National Bank raised its stake in shares of Elanco Animal Health by 136.7% during the third quarter. Huntington National Bank now owns 1,882 shares of the company’s stock worth $38,000 after buying an additional 1,087 shares during the last quarter. Whittier Trust Co. of Nevada Inc. lifted its holdings in Elanco Animal Health by 80.3% in the third quarter. Whittier Trust Co. of Nevada Inc. now owns 2,021 shares of the company’s stock valued at $42,000 after buying an additional 900 shares during the period. Farther Finance Advisors LLC boosted its stake in Elanco Animal Health by 79.3% in the third quarter. Farther Finance Advisors LLC now owns 2,151 shares of the company’s stock valued at $43,000 after acquiring an additional 951 shares during the last quarter. Finally, First Horizon Advisors Inc. boosted its stake in Elanco Animal Health by 184.3% in the second quarter. First Horizon Advisors Inc. now owns 3,724 shares of the company’s stock valued at $53,000 after acquiring an additional 2,414 shares during the last quarter. Institutional investors own 97.48% of the company’s stock.

Insider Transactions at Elanco Animal Health

In other Elanco Animal Health news, Director Lawrence Erik Kurzius purchased 10,000 shares of the firm’s stock in a transaction that occurred on Friday, December 12th. The shares were acquired at an average cost of $21.30 per share, for a total transaction of $213,000.00. Following the completion of the purchase, the director owned 131,773 shares of the company’s stock, valued at approximately $2,806,764.90. The trade was a 8.21% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Jeffrey N. Simmons bought 22,000 shares of the stock in a transaction dated Thursday, December 11th. The shares were acquired at an average cost of $21.75 per share, for a total transaction of $478,500.00. Following the completion of the acquisition, the chief executive officer directly owned 167,000 shares of the company’s stock, valued at approximately $3,632,250. This trade represents a 15.17% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have purchased a total of 43,450 shares of company stock worth $937,883 in the last ninety days. 0.89% of the stock is currently owned by company insiders.

Elanco Animal Health Trading Down 1.1%

NYSE ELAN opened at $23.68 on Wednesday. Elanco Animal Health Incorporated has a 12 month low of $8.02 and a 12 month high of $27.72. The company has a current ratio of 2.17, a quick ratio of 1.08 and a debt-to-equity ratio of 0.60. The stock has a 50 day moving average of $24.50 and a 200-day moving average of $22.14. The company has a market cap of $11.77 billion, a PE ratio of -49.32, a PEG ratio of 3.04 and a beta of 1.83.

Elanco Animal Health (NYSE:ELAN) last issued its earnings results on Tuesday, February 24th. The company reported $0.13 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.11 by $0.02. Elanco Animal Health had a negative net margin of 4.92% and a positive return on equity of 7.16%. The company had revenue of $1.14 billion for the quarter, compared to analysts’ expectations of $1.09 billion. During the same period in the prior year, the firm earned $0.14 EPS. Elanco Animal Health’s quarterly revenue was up 12.2% compared to the same quarter last year. Elanco Animal Health has set its Q1 2026 guidance at 0.330-0.36 EPS and its FY 2026 guidance at 1.000-1.060 EPS. On average, equities research analysts anticipate that Elanco Animal Health Incorporated will post 0.91 EPS for the current fiscal year.

Analyst Ratings Changes

A number of analysts recently weighed in on the stock. Weiss Ratings reiterated a “sell (d+)” rating on shares of Elanco Animal Health in a research report on Monday, December 29th. Piper Sandler raised shares of Elanco Animal Health from a “neutral” rating to an “overweight” rating and upped their target price for the company from $24.00 to $30.00 in a research note on Thursday, January 22nd. JPMorgan Chase & Co. increased their target price on shares of Elanco Animal Health from $24.00 to $28.00 and gave the stock an “overweight” rating in a report on Thursday, February 19th. KeyCorp lifted their price target on shares of Elanco Animal Health from $27.00 to $29.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 25th. Finally, Barclays assumed coverage on shares of Elanco Animal Health in a report on Tuesday, December 9th. They issued an “overweight” rating and a $30.00 price target for the company. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $27.67.

Elanco Animal Health Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.